Advertisement

Activation of MK5/PRAK by the atypical MAP kinase ERK3 defines a novel signal transduction pathway

Ole‐Morten Seternes, Theresa Mikalsen, Bjarne Johansen, Espen Michaelsen, Chris G Armstrong, Nick A Morrice, Benjamin Turgeon, Sylvain Meloche, Ugo Moens, Stephen M Keyse

Author Affiliations

  1. Ole‐Morten Seternes*,1,
  2. Theresa Mikalsen2,
  3. Bjarne Johansen2,
  4. Espen Michaelsen1,
  5. Chris G Armstrong3,,
  6. Nick A Morrice3,
  7. Benjamin Turgeon4,
  8. Sylvain Meloche4,
  9. Ugo Moens2 and
  10. Stephen M Keyse*,5
  1. 1 Department of Pharmacology, Institute of Medical Biology, University of Tromsø, Tromsø, Norway
  2. 2 Department of Biochemistry, Institute of Medical Biology, University of Tromsø, Tromsø, Norway
  3. 3 MRC Protein Phosphorylation Unit, School of Life Sciences, University of Dundee, Dundee, UK
  4. 4 Department of Molecular Biology, Institut de Recherche en Immunovirologie et Cancerologie, Universite de Montreal, Quebec, Canada
  5. 5 Cancer Research UK, Molecular Pharmacology Unit, Biomedical Research Centre, Level 5, Ninewells Hospital, Dundee, UK
  1. *Corresponding authors. Department of Pharmacology, Institute of Medical Biology, University of Tromsø, 9037 Tromsø, Norway. Tel.: +47 77 64 65 06; Fax: +47 77 64 53 10; E-mail: olems{at}fagmed.uit.noCancer Research UK, Molecular Pharmacology Unit, Biomedical Research Centre, Level 5, Ninewells Hospital, Dundee DD1 9SY, UK. Tel.: +44 1382 632 622; Fax: +44 1382 669 993; E-mail: stephen.keyse{at}cancer.org.uk
  • Present address: Invitrogen, 501 Charmany Drive, Madison, WI, USA

View Full Text

This article has a correction. Please see:

You do not have access to the full text of this article, the first page of the PDF of this article appears below.

PDF extract preview

Subscribers, please sign in with your username and password.

Log in through your institution